FINHUB Insights

DXCM · Q1 FY25 · Jan 1 – Mar 31, 2025

Dexcom Q1 FY25: where the revenue came from and where it went

Dexcom Q1 FY25: revenue $1B (+12% year over year). Net profit $0.1B. Largest cohort United States $0.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 1, 2025 10-Q
Sankey diagram of Dexcom's income statement for Q1 FY25: revenue of $1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1B +12% year over year
Gross profit$0.6B 57% margin
Operating profit$0.1B 13% margin
Net profit$0.1B 10% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 1 100% +12%
United States 0.8 80%
International 0.3 30%
Cost of revenue−0.440%
Gross profit0.657% margin−4pp
Research & development−0.114%−1pp
Sales & marketing−0.17%+0pp
SG&A−0.330%−5pp
Operating profit0.113% margin+2pp
Net profit0.110%−6pp
Filing on EDGAR More quarters of DXCM

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters